An End-of-Study Subgroup Analysis of Black Patients from the Phase 2 Griffin Study of Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM)

Saved in:
Bibliographic Details
Published in:Blood 2022-11, Vol.140 (Supplement 1), p.10154-10156
Main Authors: Nooka, Ajay K., Kaufman, Jonathan L., Rodriguez, Cesar, Jakubowiak, Andrzej, Efebera, Yvonne A., Reeves, Brandi, Wildes, Tanya M., Holstein, Sarah A., Anderson, Larry D., Badros, Ashraf Z., Shune, Leyla O., Chari, Ajai, Pei, Huiling, Cortoos, Annelore, Patel, Sharmila, Lin, Thomas S., Richardson, Paul G., Usmani, Saad, Voorhees, Peter M.
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:0006-4971
1528-0020
DOI:10.1182/blood-2022-162473